4-Amino-2-(2,6-dioxopiperidin-3-yl)-7-hydroxyisoindoline-1,3-dione

Catalog No. :
ACULPF725
CAS No. :
1547162-46-8
Molecular Formula :
C13H11N3O5
Molecular Weight :
289.25

IUPAC Name:4-amino-2-(2,6-dioxopiperidin-3-yl)-7-hydroxyisoindoline-1,3-dione

4-Amino-2-(2,6-dioxopiperidin-3-yl)-7-hydroxyisoindoline-1,3-dione structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg99%$56.00Login to see priceIn stockInquiry
250mg99%$108.00Login to see priceIn stockInquiry
1g99%$294.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4-Amino-2-(2,6-dioxopiperidin-3-yl)-7-hydroxyisoindoline-1,3-dione
IUPAC Name4-amino-2-(2,6-dioxopiperidin-3-yl)-7-hydroxyisoindoline-1,3-dione
Molecular FormulaC13H11N3O5
Molecular Weight289.25
SMILESO=C1N(C(CC2)C(NC2=O)=O)C(C3=C1C(O)=CC=C3N)=O
InChI KeyDNODJHQYSZVNMH-UHFFFAOYSA-N
SynonymCC-17369;Pomalidomide M16;1H-Isoindole-1,3(2H)-dione, 4-amino-2-(2,6-dioxo-3-piperidinyl)-7-hydroxy-;4-amino-2-(2,6-dioxopiperidin-3-yl)-7-hydroxyisoindoline-1,3-dione;M16(CC-17369);Pomalidomide metabolite M16;UNII-2Z346T86O9
CAS No.1547162-46-8

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACULPF725 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACULPF725 route product structure diagram
    ACULPF7251547162-46-8 In Stock
Inquiry

2. ACULPF725 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACULPF725 route product structure diagram
    ACULPF7251547162-46-8 In Stock
Inquiry

Comments (0)